Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?

Simply Wall St.08-03

Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656376040?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","is_english":true,"pubTime":"2026-08-03 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656376040","market":"nz","top_or_hot":-1,"title":"Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-03 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th","article_id":"2656376040","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656376040","pubTimestamp":1785755802,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals.\nSee our latest analysis for Regeneron Pharmaceuticals.\nAt a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"再生元制药 (REGN) 公布强劲的第二季度收入，上涨空间是否已经被消化？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals. See our latest analysis for Regeneron Pharmaceuticals. At a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following recent earnings, dividend news and the Telix collaboration. If you are looking for more ideas in a similar space, this could be a good moment to scan for other healthcare AI opportunities using the Simply Wall St screener for 41 healthcare AI stocks With Regeneron Pharmaceuticals rallying after solid revenue figures but softer earnings per share, along with fresh income and pipeline news, are investors now paying for business progress or a swing in sentiment around the stock’s outlook on value? AdvertisementMost Popular Narrative: 8.5% Undervalued Regeneron Pharmaceuticals most followed narrative points to a fair value of $833.31 against the last close of $762.63, which frames the current rally against analyst cash flow and earnings assumptions.  Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.  Read the complete narrative. Curious what kind of revenue path and profit profile are baked into that fair value? The narrative leans on specific growth, margin and valuation multiples that may surprise you. Result: Fair Value of $833.31 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Regeneron Pharmaceuticals still faces key pressure points, including EYLEA competition and pricing risk, along with questions over whether elevated R&D spend will translate into commercially successful new drugs. Find out about the key risks to this Regeneron Pharmaceuticals narrative. Next Steps Given the mixed signals in this Regeneron Pharmaceuticals story, it makes sense to review the underlying data yourself and act while the narrative is still forming. To see what investors view as the key positives, take a closer look at the 2 key rewards Looking for more investment ideas beyond Regeneron Pharmaceuticals? If you want to build on what you have learned about Regeneron Pharmaceuticals, this is a strong moment to widen your watchlist with focused stock ideas.  Spot opportunities with attractive valuations by scanning companies highlighted in the 55 high quality undervalued stocks. Strengthen your income potential by reviewing businesses featured in the 9 dividend fortresses. Reduce portfolio stress by checking out companies identified through the 81 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656376040","isCrawlerRequest":true}